Jeremy Barton

Jeremy Barton joined Seattle Genetics in November 2004.
In his role as Senior Medical Director, Dr. Barton is responsible for the clinical development activities of a number of the company's product candidates.
Prior to joining Seattle Genetics, he was a clinical development consultant to multiple biotechnology companies in the United Kingdom.
Previously, Dr. Barton was with Millennium Pharmaceuticals in London as Director of Clinical Research, Oncology, where he was involved in European drug development and commercialization activities.
Before that, he held senior clinical research positions at Elan Pharmaceuticals, Astra Zeneca and Glaxo Wellcome covering all phases of oncology drug development, working with cytotoxics, biologicals and signal transduction inhibitors.
Dr. Barton received his medical training at Oxford University and at University College Hospital Medical School in London.
His post graduate experience is in internal medicine and clinical oncology and he is board certified in medical oncology and radiation oncology.
Dr. Barton is a member of the Royal College of Physicians in the U.K.
and is a fellow of the Royal College of Radiologists